B-cell acute lymphoblastic leukemia (B-ALL) is the most common pediatric malignancy, accounting for 20-25% of all new cancer diagnoses in North American children each year.
The leukemia arises, most commonly after a latency of 3-5 years, from a preleukemic B cell precursor population generated
